-amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia

被引:69
作者
Mueller, Martijn L. T. M. [1 ]
Frey, Kirk A. [1 ,2 ]
Petrou, Myria [1 ,3 ]
Kotagal, Vikas [2 ]
Koeppe, Robert A. [1 ]
Albin, Roger L. [2 ,4 ,5 ]
Bohnen, Nicolaas I. [1 ,2 ,4 ,5 ]
机构
[1] Univ Michigan, Dept Radiol, Ann Arbor, MI 48105 USA
[2] Univ Michigan, Dept Neurol, Ann Arbor, MI 48105 USA
[3] Johns Hopkins Univ, Russell H Morgan Dept Radiol, Baltimore, MD USA
[4] VAAAHS, Neurol Serv, Ann Arbor, MI USA
[5] VAAAHS, GRECC, Ann Arbor, MI USA
基金
美国国家卫生研究院;
关键词
Parkinson's disease; -amyloid; dopamine; PET; MDS-UPDRS; MILD COGNITIVE IMPAIRMENT; QUALITY-OF-LIFE; ALZHEIMERS-DISEASE; EXECUTIVE FUNCTION; MOTOR SUBTYPE; VARIABILITY; PROGRESSION; CONTRIBUTES; DYSFUNCTION; DEPOSITION;
D O I
10.1002/mds.25213
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Although motor impairments in Parkinson's disease (PD) are attributed to nigrostriatal dopaminergic denervation, postural instability and gait difficulty (PIGD) features are less responsive to dopaminergic medications. PIGD features are a risk factor also for the development of dementia in PD (PDD). These observations suggest that nondopaminergic mechanisms may contribute to axial motor impairments. The aim was to perform a correlative PET study to examine the relationship between neocortical -amyloid deposition ([11C]-Pittsburgh Compound B), nigrostriatal dopaminergic denervation ([11C]-dihydrotetrabenazine), and PIGD feature severity in PD patients at risk for dementia. This was a cross-sectional study of 44 PD patients (11 female and 33 male; 69.5 +/- 6.6 years of age; 7.0 +/- 4.8 years motor disease duration; mean H & Y stage: 2.7 +/- 0.5) who underwent PET, motor feature severity assessment using the Movement Disorder Society revised UPDRS, and the Dementia Rating Scale (DRS). Linear regression (R2adj = 0.147; F4,39 = 2.85; P = 0.036) showed that increased PIGD feature severity was associated with increased neocortical [11C]-Pittsburgh Compound B binding ( = 0.346; t39 = 2.13; P = 0.039) while controlling for striatal [11C]-dihydrotetrabenazine binding, age, and DRS total score. Increased neocortical -amyloid deposition, even at low-range levels, is associated with higher PIGD feature severity in PD patients at risk for dementia. This finding may explain why the PIGD motor phenotype is a risk factor for the development of PDD. (c) 2012 Movement Disorder Society
引用
收藏
页码:296 / 301
页数:6
相关论文
共 46 条
[1]   The epidemiology of dementia associated with Parkinson disease [J].
Aarsland, Dag ;
Kurz, Martin Wilhelm .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2010, 289 (1-2) :18-22
[2]   Changes in motor subtype and risk for incident dementia in Parkinson's disease [J].
Alves, Guido ;
Petter Larsen, Jan ;
Emre, Murat ;
Wentzel-Larsen, Tore ;
Aarsland, Dag .
MOVEMENT DISORDERS, 2006, 21 (08) :1123-1130
[3]  
[Anonymous], 2011, PARKINSONS DIS
[4]  
Beauchet Olivier, 2008, Neuropsychiatr Dis Treat, V4, P155
[5]   Influence of dopaminergic medication on automatic postural responses and balance impairment in Parkinson's disease [J].
Bloem, BR ;
Beckley, DJ ;
vanDijk, JG ;
Zwinderman, AH ;
Remler, MP ;
Roos, RAC .
MOVEMENT DISORDERS, 1996, 11 (05) :509-521
[6]   Postural control, gait, and dopamine functions in parkinsonian movement disorders [J].
Bohnen, Nicolaas I. ;
Cham, Rakie .
CLINICS IN GERIATRIC MEDICINE, 2006, 22 (04) :797-+
[7]   Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease [J].
Bohnen, Nicolaas I. ;
Albin, Roger L. ;
Koeppe, Robert A. ;
Wernette, Kristine A. ;
Kilbourn, Michael R. ;
Minoshima, Satoshi ;
Frey, Kirk A. .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2006, 26 (09) :1198-1212
[8]   STAGING OF ALZHEIMERS-DISEASE-RELATED NEUROFIBRILLARY CHANGES [J].
BRAAK, H ;
BRAAK, E .
NEUROBIOLOGY OF AGING, 1995, 16 (03) :271-278
[9]   Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies [J].
Burn, DJ ;
Rowan, EN ;
Allan, LM ;
Molloy, S ;
T O'Brien, J ;
McKeith, IG .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2006, 77 (05) :585-589
[10]   Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease [J].
Cools, R .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2006, 30 (01) :1-23